Mizuho Issues Pessimistic Forecast for DENTSPLY SIRONA (NASDAQ:XRAY) Stock Price

DENTSPLY SIRONA (NASDAQ:XRAY) had its price target reduced by investment analysts at Mizuho from $16.00 to $14.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price objective would suggest a potential upside of 27.74% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Barrington Research boosted their price target on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research report on Monday, March 2nd. Wells Fargo & Company increased their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price target for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Monday, April 20th. Finally, Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Three investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, DENTSPLY SIRONA presently has an average rating of “Hold” and a consensus target price of $13.82.

DENTSPLY SIRONA Stock Down 1.6%

XRAY opened at $10.96 on Wednesday. The company has a market capitalization of $2.20 billion, a P/E ratio of -3.48, a P/E/G ratio of 1.32 and a beta of 0.93. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 1.03. The firm’s fifty day moving average price is $12.07 and its two-hundred day moving average price is $12.00. DENTSPLY SIRONA has a fifty-two week low of $9.85 and a fifty-two week high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The business had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. During the same quarter in the prior year, the company posted $0.43 EPS. The company’s quarterly revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, analysts anticipate that DENTSPLY SIRONA will post 1.42 EPS for the current year.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 27,555 shares of the stock in a transaction dated Monday, March 2nd. The stock was bought at an average price of $14.24 per share, for a total transaction of $392,383.20. Following the transaction, the director directly owned 27,555 shares in the company, valued at $392,383.20. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James D. Forbes acquired 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was acquired at an average price of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $124,800. This trade represents a 100.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 70,000 shares of company stock worth $956,437. Corporate insiders own 0.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA during the first quarter worth about $26,000. Goldman Sachs Group Inc. increased its stake in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC raised its position in shares of DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of DENTSPLY SIRONA by 7.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth boosted its stake in DENTSPLY SIRONA by 59.1% during the 1st quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after acquiring an additional 9,355 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.